The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

Key facts

Study ID

NCT05926102

Run by

VA Office of Research and Development

People needed

5000

Starts

2024-02-01

Expected to finish

2030-09-30

Last updated by the study team

2026-01-13

Who can join

Age: 55 and older, up to 69. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• baseline age 55-69 years
• receipt of regular VA care
• Veteran status

You may not qualify if…

• personal history of prostate cancer
• prior prostate biopsy, prostatectomy, or prostate MRI
• known carrier status of rare variant associated with cancer syndrome

Where it is running

• VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.